Vaccines and antibodies in the prevention and treatment of sepsis

Infect Dis Clin North Am. 1999 Jun;13(2):355-69, vii. doi: 10.1016/s0891-5520(05)70079-9.

Abstract

Antibodies to various core glycolipid antigens have been shown to correlate with survival from Gram-negative sepsis. Recent preclinical data also support efficacy of the anti-core glycolipid antibodies in the treatment of sepsis. Failure of some of the previous clinical trials with anti-core glycolipid antibody was probably due to inadequate levels of antibody in those preparations. Future clinical trials must ensure that sufficient amounts of anti-core glycolipid antibodies are present in the circulation of patients with sepsis.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Bacterial / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use
  • Bacterial Vaccines / immunology*
  • Bacterial Vaccines / therapeutic use
  • Endotoxins / chemistry
  • Endotoxins / immunology
  • Glycolipids / immunology
  • Gram-Negative Bacterial Infections / prevention & control
  • Gram-Negative Bacterial Infections / therapy*
  • Humans
  • O Antigens / chemistry
  • O Antigens / immunology
  • Sepsis / prevention & control
  • Sepsis / therapy*
  • Vaccination

Substances

  • Antibodies, Bacterial
  • Antibodies, Monoclonal
  • Bacterial Vaccines
  • Endotoxins
  • Glycolipids
  • O Antigens